Abraxis deal done, Celgene eyes cancer franchise

Celgene

Now that Celgene has wrapped up its $3 billion-plus buyout of Abraxis BioScience, analysts are cheering. That wasn't necessarily the case in June, when the companies announced their deal--and investors responded by selling off their stock, sending the price plummeting to $48. But as Investor's Business Daily reports, Celgene shares are now trading at near $60, and observers think the combo will eventually transform the company into a "biopharmaceutical giant."

Celgene specializes in drugs for blood cancers, with its Revlimid drug leading the company's roster. Abraxis, on the other hand, sports a promising drug for solid tumors, Abraxane. Analysts think that Celgene can beef up Abraxane sales significantly, because it already fields a cancer-drug sales force. Up to $500 million from $315 million last year, one analyst predicts.

But even more importantly, Abraxane has the potential to be a "platform drug" used to treat several forms of cancer. Now approved for breast cancers that haven't responded to other treatments, Abraxane is being tested against advanced lung cancer, malignant melanoma and advanced pancreatic cancer (all Phase III); and bladder and ovarian cancers (both Phase II).

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

"If Abraxane was a low-growth drug, the [buyout] price might be seen as steep, but it has the prospect to reinvigorate growth for Celgene," Standard & Poor's analyst Steven Silver tells IBD. We'll know more once that Phase III data starts to appear.

 

Suggested Articles

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.

Novavax will shell out $167 million for Czech manufacturer Praha Vaccines in a move to boost production of a COVID-19 vaccine past 1 billion doses.